Galmed Pharmaceuticals Ltd. (GLMD): Price and Financial Metrics
GLMD Price/Volume Stats
| Current price | $0.37 | 52-week high | $7.80 |
| Prev. close | $0.35 | 52-week low | $0.26 |
| Day low | $0.34 | Volume | 46,300 |
| Day high | $0.38 | Avg. volume | 192,585 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $0.61 | Market Cap | 1.86M |
GLMD Stock Price Chart Interactive Chart >
Galmed Pharmaceuticals Ltd. (GLMD) Company Bio
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company was founded in 2000 and is based in Tel Aviv, Israel.
Latest GLMD News From Around the Web
Below are the latest news stories about GALMED PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate GLMD as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study. |
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramch |
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationTEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to main |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday! |
GLMD Price Returns
| 1-mo | 18.14% |
| 3-mo | 9.76% |
| 6-mo | -11.36% |
| 1-year | -92.53% |
| 3-year | -99.22% |
| 5-year | -99.69% |
| YTD | -18.68% |
| 2023 | -93.93% |
| 2022 | -72.53% |
| 2021 | -41.48% |
| 2020 | -46.19% |
| 2019 | -15.37% |
Continue Researching GLMD
Want to do more research on Galmed Pharmaceuticals Ltd's stock and its price? Try the links below:Galmed Pharmaceuticals Ltd (GLMD) Stock Price | Nasdaq
Galmed Pharmaceuticals Ltd (GLMD) Stock Quote, History and News - Yahoo Finance
Galmed Pharmaceuticals Ltd (GLMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...